Immunotherapy for leukemia targeting the Wilms' tumor gene

Leukemia and Lymphoma

Volumn 42, Issue 3, 2001, Pages 267-273

  Yasukawa, M ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic T lymphocytes; HLA; Immunotherapy; Leukemia; WT1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD8 ANTIGEN; HLA ANTIGEN; PEPTIDE; TRANSCRIPTION FACTOR; ZINC FINGER PROTEIN;

ACUTE LEUKEMIA; BINDING SITE; BLAST CELL CRISIS; BONE MARROW CELL; CANCER CELL; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GENE EXPRESSION; LEUKEMIA; LEUKEMIA CELL; LYMPHOCYTE CLONE; LYMPHOMA CELL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0034902311     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109064583     Document Type: Review

References (36)

1. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
2. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping
3. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1
4. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
5. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus
6. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product
7. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1
8. Regulation of the proto-oncogene bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1
9. The candidate Wilms' tumour gene is involved in genitourinary development
10. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor
11. WT1 is required for early kidney development
12. The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma
13. Expression of the Wilms' tumor gene WT1 in the murine urogenital system
14. Expression of the Wilms' timor gene (WT1) in human leukemias
15. Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells
16. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
17. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis
18. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro
19. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia
20. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
21. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
22. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndrome
23. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels
24. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis
25. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines
26. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide
27. Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors
28. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
29. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1
30. Cancer immunotherapy targeting Wilms' tumor gene WT1 product
31. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors
32. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression
33. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in human malignant mesothelioma
34. Constitutive expression of the Wilms tumor suppresor gene (WT1) in renal cell carcinoma
35. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth
36. Cytotoxic T-lymphocyte response elicited to Wilms' tumor gene WT1 product by DNA vaccination